Cisatracurium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cisatracurium
Accession Number
DB13450
Type
Small Molecule
Groups
Approved, Experimental
Description

Cisatracurium is a stereoisomer of atracurium and an intermediate-onset/intermediate-duration neuromuscular blocking agent. It is a nondepolarizing skeletal muscle relaxant that competitively blocks the neurotraminssion by binding to cholinergic receptors. Cisatracurium besylate is an active ingredient in intravenously administered treatment indicated for use during surgery or other procedures as an adjunct therapy to general anesthesia in the intensive care unit to relax skeletal muscles and facilitate tracheal intubation and mechanical ventilation. It is only available as a prescription drug as designated by the FDA.

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cisatracurium Besylate InjectionSolution2 mgIntravenousPfizer2015-06-01Not applicableCanada
Cisatracurium Omega Single DoseSolution2 mgIntravenousOmega Laboratories Ltd2014-01-28Not applicableCanada
Categories
UNII
QX62KLI41N
CAS number
96946-41-7
Weight
Average: 929.16
Monoisotopic: 928.507428607
Chemical Formula
C53H72N2O12
InChI Key
YXSLJKQTIDHPOT-LJCJQEJUSA-N
InChI
InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1
IUPAC Name
(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-2-(3-{[5-({3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propanoyl}oxy)pentyl]oxy}-3-oxopropyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
SMILES
COC1=CC=C(C[[email protected]@H]2C3=CC(OC)=C(OC)C=C3CC[[email protected]+]2(C)CCC(=O)OCCCCCOC(=O)CC[[email protected]@+]2(C)CCC3=CC(OC)=C(OC)C=C3[[email protected]]2CC2=CC=C(OC)C(OC)=C2)C=C1OC

Pharmacology

Indication
Not Available
Structured Indications
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCisatracurium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCisatracurium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Cisatracurium.Investigational
AldoxorubicinAldoxorubicin may increase the respiratory depressant activities of Cisatracurium.Investigational
AmikacinAmikacin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
AnnamycinAnnamycin may increase the respiratory depressant activities of Cisatracurium.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Cisatracurium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Cisatracurium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational
Botulinum Toxin Type BCisatracurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Cisatracurium.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational, Vet Approved
ClindamycinClindamycin may increase the neuromuscular blocking activities of Cisatracurium.Approved, Vet Approved
ColistimethateColistimethate may increase the neuromuscular blocking activities of Cisatracurium.Approved, Vet Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational, Vet Approved
CymarinCisatracurium may increase the arrhythmogenic activities of Cymarin.Experimental
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Cisatracurium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Cisatracurium.Approved
DeslanosideCisatracurium may increase the arrhythmogenic activities of Deslanoside.Approved
DibekacinDibekacin may increase the respiratory depressant activities of Cisatracurium.Experimental
DigitoxinCisatracurium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCisatracurium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Cisatracurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Cisatracurium.Investigational, Vet Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational, Vet Approved
EpirubicinEpirubicin may increase the respiratory depressant activities of Cisatracurium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Cisatracurium.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Cisatracurium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved, Vet Approved
GeneticinGeneticin may increase the respiratory depressant activities of Cisatracurium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Cisatracurium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Cisatracurium.Experimental
GitoformateCisatracurium may increase the arrhythmogenic activities of Gitoformate.Experimental
GPX-150GPX-150 may increase the respiratory depressant activities of Cisatracurium.Investigational
Hygromycin BHygromycin B may increase the respiratory depressant activities of Cisatracurium.Vet Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Cisatracurium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Cisatracurium.Experimental
KanamycinKanamycin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational, Vet Approved
Lanatoside CCisatracurium may increase the arrhythmogenic activities of Lanatoside C.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Cisatracurium.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Cisatracurium.Approved
LorpiprazoleThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Lorpiprazole.Approved
Magnesium HydroxideMagnesium Hydroxide may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Cisatracurium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Cisatracurium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational, Vet Approved
MetildigoxinCisatracurium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetrizamideMetrizamide may increase the respiratory depressant activities of Cisatracurium.Approved
MicronomicinMicronomicin may increase the respiratory depressant activities of Cisatracurium.Experimental
MinocyclineMinocycline may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational
NeamineNeamine may increase the respiratory depressant activities of Cisatracurium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Cisatracurium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
OleandrinCisatracurium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OuabainCisatracurium may increase the arrhythmogenic activities of Ouabain.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
PeruvosideCisatracurium may increase the arrhythmogenic activities of Peruvoside.Experimental
PirarubicinPirarubicin may increase the respiratory depressant activities of Cisatracurium.Investigational
PiretanidePiretanide may decrease the neuromuscular blocking activities of Cisatracurium.Experimental
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Cisatracurium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Cisatracurium.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Cisatracurium.Approved, Vet Approved
ProcainamideProcainamide may increase the neuromuscular blocking activities of Cisatracurium.Approved
ProscillaridinCisatracurium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Cisatracurium.Experimental
QuinidineQuinidine may increase the neuromuscular blocking activities of Cisatracurium.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Cisatracurium.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
SabarubicinSabarubicin may increase the respiratory depressant activities of Cisatracurium.Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Cisatracurium.Investigational
SP1049CSP1049C may increase the respiratory depressant activities of Cisatracurium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Cisatracurium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
TobramycinTobramycin may increase the respiratory depressant activities of Cisatracurium.Approved, Investigational
TorasemideTorasemide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Cisatracurium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Cisatracurium.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Cisatracurium.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Cisatracurium.Experimental
Food Interactions
Not Available

References

General References
  1. GlaxoSmithKline: NIMBEX injection product information [Link]
External Links
PubChem Compound
62887
PubChem Substance
347829301
ChemSpider
56615
ChEMBL
CHEMBL1201248
Wikipedia
Cisatracurium
ATC Codes
M03AC11 — Cisatracurium
AHFS Codes
  • 12:20.20 — Neuromuscular Blocking Agents
FDA label
Download (492 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Enrolling by InvitationBasic ScienceARDS, Human / Critical Illness / Neuromuscular Blockade / Paralysis / Respiratory Distress Syndrome, Adult / Respiratory Failure1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntravenous2 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.32e-05 mg/mLALOGPS
logP3.41ALOGPS
logP-0.96ChemAxon
logS-7.6ALOGPS
pKa (Strongest Acidic)19.02ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area126.44 Å2ChemAxon
Rotatable Bond Count26ChemAxon
Refractivity280.68 m3·mol-1ChemAxon
Polarizability106 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Benzylisoquinolines
Direct Parent
Benzylisoquinolines
Alternative Parents
Tetrahydroisoquinolines / Dimethoxybenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / Aralkylamines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds
show 6 more
Substituents
Benzylisoquinoline / Tetrahydroisoquinoline / Dimethoxybenzene / O-dimethoxybenzene / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Aralkylamine / Alkyl aryl ether
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:42 / Updated on February 13, 2018 09:54